FDA Adopts Super Intelligence (SI) Terminology Across Agency Communications
REGULATORY UPDATE
The U.S. Food and Drug Administration (FDA) announced that beginning November 16, 2026, it will use the terms Super Intelligence (SI) and Super Intelligence Systems in newly issued public-facing documents and communications, replacing references to Artificial Intelligence (AI) where applicable.
This change follows Executive Order 14434 – Inaugurating the Era of Super Intelligence, issued by the White House on September 29, 2026.
WHAT IS CHANGING?
| Previous Terminology | New Terminology |
| Artificial Intelligence (AI) | Super Intelligence (SI) |
| AI Systems | Super Intelligence Systems |
- Official correspondence
- Public communications
- Agency websites
- Reports and policy documents
- Non-statutory guidance materials
WHAT IS NOT CHANGING?
The FDA has clarified that this update:- Does not create new regulatory requirements
- Does not affect current FDA regulations or guidance documents
- Does not require changes to product names, labeling, or submissions
- Does not alter existing compliance expectations for regulated industry
IMPACT ON INDUSTRY
Companies may begin seeing the term Super Intelligence (SI) appear in:- FDA guidance documents
- Regulatory communications
- Scientific publications
- Digital health discussions
- Manufacturing innovation programs
- Public workshops and presentations
Potentially affected sectors include:
- Pharmaceutical Development
- Biotechnology
- Medical Devices & SaMD
- Advanced Manufacturing
- Clinical Trial Analytics
- Pharmacovigilance & Quality Systems
RECOMMENDED ACTIONS
Regulatory Affairs Teams
- Monitor future FDA communications for SI terminology.
- Update regulatory intelligence monitoring programs.
- Maintain current submission practices unless otherwise specified by FDA.
Quality & Compliance Teams
- Educate stakeholders regarding the terminology shift.
- Continue following existing FDA regulations and guidance documents as written.
Technology & Innovation Teams
- Expect future references to SI in FDA communications involving AI-enabled products and technologies.
MASUU REGULATORY INSIGHT
While this announcement primarily represents a Federal terminology change, it reflects the increasing strategic focus on advanced computational technologies across healthcare, life sciences, manufacturing, and regulatory science.
Masuu Global developing AI-enabled software, predictive analytics platforms, digital health solutions, automated manufacturing systems, or data-driven quality tools should remain attentive to future FDA policy developments that may further shape the regulatory landscape.
KEY TAKEAWAY
- AI → SI in FDA Communications
- No New Regulatory Requirements
- Existing FDA Regulations and Guidance Remain Unchanged
- Industry Should Monitor Future FDA Communications for Continued Implementation
